cpc 1 jan 12 2008 dr ruenger

Upload: khawar93

Post on 10-Apr-2018

215 views

Category:

Documents


0 download

TRANSCRIPT

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    1/92

    CPC

    Supervisor

    Dr. Thomas Ruenger

    Jan. 12, 2009

    Muhammad Khawar Nazir

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    2/92

    Case 1

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    3/92

    Picture 1/4

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    4/92

    Picture 2/4

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    5/92

    Picture 3/4

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    6/92

    Picture 4/4

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    7/92

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    8/92

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    9/92

    Verocay body of a neurilemoma, consisting of tight, discrete

    aggregates of spindle-shaped, palisaded nuclei with a central

    fibrillary area, representing collections of cytoplasmic

    processes of tumorous Schwann cells

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    10/92

    Hypercellular areas often show nuclear palisading and Verocay

    bodies.

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    11/92

    Schwannoma "Neurilemmoma

    Tumor originating from the Schwann cells

    Myelin sheath which covers peripheral nerves isproduced by the Schwann cells

    Tumor cells always stay on the outside of the nerve

    Relatively slow growing

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    12/92

    Schwannoma "Neurilemmoma

    Mostly benign and less than 1% become malignant known asmalignant peripheral nerve sheath tumour or malignant

    Schwannoma or neurofibrosarcoma

    Schwannomas can arise from a genetic disorder calledneurofibromatosis

    Schwannomas can be removed surgically, but can then recur

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    13/92

    A solid lesion arises within a nervecomposed of a single fascicle

    The tumor is composed of Schwann cell

    proliferation within the epineurium andperipherallydisplaced nerve fibers,resulting in nodular eccentric growth

    No capsule is formed in the early growthphase

    The larger tumor (bottom) slightlyincreases the size of the parent nerve andeventually becomes separated fromsurrounding fascicles by a capsule formedfrom the perineurium and epineurium.Occasional axons are present.

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    14/92

    HistopatholgyAntoni A & Antoni B Tissues

    Encapsulated subcutaneous tumor

    with

    1) Cellular areas ( Antoni A tissue )

    and / or

    2)Edematous myxoid areas (Antoni B tissue)

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    15/92

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    16/92

    Vecoray Bodies

    Spindle cells in Antoni A tissue line up in twoparallel rows separated by areas without

    nuclei

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    17/92

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    18/92

    Case 2

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    19/92

    Picture 1/6

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    20/92

    Picture 2/6

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    21/92

    Picture 3/6

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    22/92

    Picture 4/6

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    23/92

    Picture 5/6

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    24/92

    Picture 6/6

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    25/92

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    26/92

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    27/92

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    28/92

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    29/92

    Kaposi Sarcoma

    Controversial whether Kaposi's sarcoma (KS) representsneoplasia or hyperplasia;

    All clinical variants are viewed as a virally induced disease

    human herpesvirus-8 (HHV-8) is the implicated agent

    Multifocal systemic disease with 4 principal clinicalvariants:

    (1) chronic or classic KS;

    (2) African endemic KS, including a fulminantlymphadenopathic type;

    (3) KS in iatrogenically immunocompromised patients; and

    (4) AIDS-related epidemic KS

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    30/92

    Key Features

    Cutaneous lesions present as variably distributed pink patches,blueviolet to black nodules or plaques, and polyps, depending onthe clinical variant and stage

    The histologic appearance of KS does not vary significantly

    between clinical subtypes, but does vary with stage of the lesion

    Most cases in childhood, with or without HIV infection, are of thelymphadenopathic type and are rapidly fatal due to visceraldissemination

    Because of multifocality, treatment with chemotherapy and/orradiation is favored over surgery

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    31/92

    Kaposi's sarcoma

    Tumor caused byHuman herpesvirus 8

    (HHV8), also known as Kaposi's sarcoma-

    associated herpesvirus (KSHV)

    It was originally described by Moritz Kaposi, a

    Hungarian dermatologist practicing at the

    University of Vienna in 1872

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    32/92

    Kaposi sarcoma

    KS is a neoplasm that often manifests withmultiple vascular nodules in the skin and otherorgans.

    Although true metastases appear to occur, a

    multifocal origin is most common. The pattern of KS is variable, with a course

    ranging from indolent (only skin manifestations)to fulminant (extensive visceral involvement).

    KS also may arise primarily in the oral mucosa,lymph nodes, and/or viscera without skininvolvement.

    KS initially may be evident in any organ of thebody

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    33/92

    3 FORMS

    1)Localized nodular

    2)Locally aggressive3)Generalized

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    34/92

    6 stages

    1. Patch

    2. Plaque

    3. Nodular4. Exophytic

    5. Infiltrative

    6. Lymphadenopathic

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    35/92

    Differential Diagnoses

    1. BacillaryAngiomatosis

    2. Blue Rubber Bleb Nevus Syndrome3. Nevi, Melanocytic

    4. Pyogenic Granuloma (Lobular Capillary

    Hemangioma)5. Tufted Angioma

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    36/92

    Histopathology

    Slitlike spaces

    Vessels sometimes appear as lymphangiomatosis,

    without erythrocytes

    Promontory sign

    small blood vessel and its stroma project like a

    promontory into a vascular space.

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    37/92

    Treatment

    Surgical excision,

    Radiotherapy

    Intralesional Outpatient low-dose vinblastine

    chemotherapy

    Radiotherapy Laser

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    38/92

    Case 3

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    39/92

    Picture 1/5

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    40/92

    Picture 2/5

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    41/92

    Picture 3/5

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    42/92

    Picture 4/5

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    43/92

    Picture 5/5

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    44/92

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    45/92

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    46/92

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    47/92

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    48/92

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    49/92

    Porphyria

    Uncommon to rare group of porphyrin

    metabolidsm disorders

    Most of them present as photodermatitis with

    papules or vesicles mostly on sun exposed skin

    Acute and Non Acute Types

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    50/92

    Porphyria Cutanea Tarda

    Tarda means Late ( adult onset)

    Non Acute Type

    Most common type of porphyria. It results from a

    decreased catalytic activity of uroporphyrinogendecarboxylase, the fifth enzyme in heme biosynthesis

    Cutaneous Manifestations : increased photosensitivity andskin fragility as well as blistering, erosions, crusts, milia and

    scars in sun-exposed sites

    Postinflammatory hyperpigmentation, hypertrichosis,scarring alopecia, and morpheaform and sclerodermoidchanges can be observed

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    51/92

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    52/92

    Types

    Depending upon the major site of expression of the

    uroporphyrinogen decarboxylase, at least 2 types canbe distinguished:

    1) Sporadic (acquired) variant, designated type I PCT, inwhich the enzymatic deficiency is exclusively expressedin the liver

    2) Autosomal dominant familial (hereditary) variant,designated type II PCT, in which the catalytic enzymaticdefect is detected in all tissues

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    53/92

    Histologic & Immunofluorescence Microscopy Findings

    Subepidermal blister with a minimal cell-poor dermalinflammatory infiltrate

    Festooning of the dermal papillae (very well preservedpapillae projecting into blister ) with PAS-positivedeposits within the walls of blood vessels (PAS stain)

    Direct immunofluorescence with prominent ring-shaped staining around blood vessels and lesser linearstaining along the dermalepidermal junction.

    Diff ti l Di i

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    54/92

    Differential Diagnosis

    Other types of cutaneous porphyria that manifesting blistering,

    Mild variants of congenital erythropoietic porphyria

    Hepatoerythropoietic porphyria

    Variegate porphyria

    Hereditary coproporphyria.

    Pseudoporphyria

    Epidermolysis bullosa acquisita

    Polymorphous light eruption

    Phototoxic and bullous drug eruptions

    Hydroa vacciniforme

    All above diseases can easily be differentiated from PCT bymeasuring urinary and stool porphyrins

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    55/92

    Therapeutic Approaches

    1. Photoprotection, e.g. broad-spectrum sunscreens and/orprotective clothing

    2. Avoidance of sunlight exposure and trauma

    3. Cease alcohol ingestion; stop estrogen therapy

    4. Phlebotomy: 400500 ml every 2 weeks over 3 to 6 months

    5. Low-dose hydroxychloroquine or chloroquine

    6. Measurement of urinary porphyrin excretion to monitortherapeutic outcome

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    56/92

    Case 4

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    57/92

    Picture 1/6

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    58/92

    Picture 2/6

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    59/92

    Picture 3/6

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    60/92

    Picture 4/6

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    61/92

    Picture 5/6

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    62/92

    Picture 6/6

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    63/92

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    64/92

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    65/92

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    66/92

    Leishmaniasis

    Synonyms:

    Old World cutaneous leishmaniasis: oriental sore, Delhi

    boil, Baghdad boil

    New World cutaneous and mucocutaneousleishmaniasis: chiclero's ulcer (Mexico), uta and espundia(Peru), ulcera de Bauru (Brazil), bush or forest yaws, pian

    boi (Guyanas)

    Visceral leishmaniasis: kala-azar and Dumdum fever

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    67/92

    Leishmaniasis

    Chronic parasitic (protozoan) disease in whichorganisms are found within phagolysosomes of themononuclear phagocyte system

    Most common cutaneous finding is a papule thatdevelops at the site of inoculation and then enlarges andulcerates

    Vector is a sandfly infected with promastigotes

    Worldwide distribution, but endemic in LatinAmerica, the Mediterranean basin, and parts ofAsia andAfrica

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    68/92

    Sand Fly

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    69/92

    Life cycle of the Leishmania parasite

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    70/92

    Leishmaniasis

    Leishmaniasis encompasses a spectrum ofchronic infections in humans and several animalspecies

    It is caused byover 15 species ofLeishmania,flagellated protozoans belonging to the orderKinetoplastidae

    Transmission is via the bite of sandflies from thegenera Phlebotomus and Lutzomyia.

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    71/92

    Clinical Features

    Begins as a small, well-circumscribed papule at theinoculation site that may enlarge into a nodule orplaque and then become ulcerated or verrucous

    Exposed sites are most commonly involved

    Lesions are often solitary but they may be multiple,with the formation of satellites or lymphatic spread

    Majority of acute cutaneous infections resolvespontaneously with scarring but some may becomechronic or disseminated.

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    72/92

    Histopatholgy

    Epidermis normal, atrophic, hyperplastic, or

    ulcerated

    Diffuse mixed granulomatous dermal infiltrateof lymphocytes, histiocytes, plasma cells,

    neutrophils, and multinucleated giant cells

    Occasional caseational necrosis

    Fibrosis in older lesions

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    73/92

    Diagnosis

    Diagnosis can be confirmed by demonstrating the

    presence ofAmastigotes in dermal macrophages

    byskin biopsy, dermal scrapings or fine-needle

    aspiration

    Giemsa, Wright or Feulgen stains are used to

    demonstrate the organisms in smears and tissue:the cytoplasm appears blue, the nucleus pink and

    the kinetoplast a deep red

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    74/92

    Differential Diagnosis

    Persistent arthropod bites

    Basal cell carcinomas

    Atypical mycobacterioses

    Mucocutaneous leishmaniasis can resemble otherinfections such as paracoccidioidomycosis, nomaand tertiary syphilis

    In addition, Wegener's granulomatosis andangiocentric NK/T-cell lymphoma must beconsidered when ulcerative mucocutaneouslesions affect the central part of the face

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    75/92

    Treatment

    Pentavalent antimonials - Standard therapy

    for New World leishmaniasis as well as more

    severe cutaneous infections

    Additional therapies :

    Heat therapy, Cryotherapy, Pentamidine,

    Itraconazole, Amphotericin B, Ketoconazole,

    Allopurinol

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    76/92

    Prevention

    Use ofinsect repellants and insecticides, as

    well as the destruction of animal reservoirs

    Akilled L. amazonensis promastigote vaccine

    has been shown to induce a Th1 response andsignificant resistance against Leishmania

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    77/92

    Case 5

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    78/92

    Picture 1/4

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    79/92

    Picture 2/4

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    80/92

    Picture 3/4

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    81/92

    Picture 4/4

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    82/92

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    83/92

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    84/92

    Venous Lake

    First described in 1956 by Bean and Walsh, whonoted how they can be easily compressed and theirtendency to occur on sun-exposed skin, especiallythe ears of elderly

    Also known as "Phlebectases" is an asymptomatic ,generally solitary, soft, compressible, dark blue toviolaceous, 0.2- to 1-cm papule

    Commonly found on sun-exposed surfaces of thevermilion border of the lip, face and ears

    Lesions generally occur among the elderly

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    85/92

    Importance

    ClinicallyInsignificant from a biological

    standpoint

    Important because of their mimicry of more

    ominous lesions, such as Melanoma and

    Pigmented Basal Cell Carcinoma.

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    86/92

    Venous Lake

    Though these lesions may resemble nodularmelanoma , the lack of induration, slowgrowth, and lightening appearance upon

    diascopy suggest against it, and indicate avascular lesion

    Additionally, lack of pulsation distinguishesthis lesion of the lower lip from a tortuoussegment of the inferior labial artery

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    87/92

    Etiology

    Unknown; however it is thought to be associated withsun exposure and sun damage, leading to a dilatedblood-filled vascular channel

    One theory is that chronic solar damage injures thevascular adventitia and the dermal elastic tissue,permitting dilatation of superficial venous structures.

    "...lined with a singled layer of flattened endothelialcells and a thin wall of fibrous tissue filled with redblood cells."

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    88/92

    Differential Diagnosis

    Angiokeratoma Circumscriptum

    Lentigo

    Basal Cell Carcinoma

    Malignant Melanoma Blue Nevi

    Nevi, Melanocytic

    CherryHemangioma

    Pyogenic Granuloma (Lobular CapillaryHemangioma) Kaposi Sarcoma

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    89/92

    Work Up

    Diascopy

    Dermoscopy

    Biopsy, If diagnosis is uncertain

    Histologic Findings

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    90/92

    Histologic Findings Single large dilated space or several interconnecting dilated

    spaces characteristically are observed in the superficial dermis

    Dilated channels have very thin walls that are lined by a singlelayer of flattened endothelium and supported by a thin layerof fibrous connective tissue

    Usually, no smooth muscle or elastic tissue is found in thevessel wall

    In rare cases, a thin and noncircumferential area suggestive ofsmooth muscle can be found instead of the fibrous tissue

    Solar elastosis and other evidence ofsun damage usually arefound in the adjacent dermis.

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    91/92

    Treatment

    Not necessary, and patients should be

    reassured of the lesion's non-malignant

    nature

    However, if treatment is sought for cosmetic

    reasons, lesions can be treated with surgical

    excision, laser therapy, infrared coagulation,cryotherapy and sclerotherapy

  • 8/8/2019 CPC 1 Jan 12 2008 Dr Ruenger

    92/92

    Thank you